Structure-Activity Relationship Studies of Pyrimido[5,4-b]indoles as Selective Toll-Like Receptor 4 Ligands

被引:22
作者
Chan, Michael [1 ]
Kakitsubata, Yuhei [2 ]
Hayashi, Tomoko [1 ]
Ahmadi, Alast [1 ]
Yao, Shiyin [1 ]
Shukla, Nikunj M. [1 ]
Oyama, Shin-ya [2 ]
Baba, Akihito [2 ]
Nguyen, Brandon [1 ]
Corr, Maripat [3 ]
Suda, Yasuo [2 ]
Carson, Dennis A. [1 ,3 ]
Cottam, Howard B. [1 ,3 ]
Wakao, Masahiro [1 ,2 ]
机构
[1] Univ Calif San Diego, Moores Canc Ctr, 9500 Gilman Dr, La Jolla, CA 92093 USA
[2] Kagoshima Univ, Dept Chem, 1-21-40 Kohrimoto, Kagoshima 8900065, Japan
[3] Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA
基金
美国国家卫生研究院;
关键词
TRANSLATING INNATE; EADOCK DSS; ACTIVATION; IMMUNITY; AGONIST; TOLL-LIKE-RECEPTOR-7; IDENTIFICATION; DISCOVERY; RESPONSES; VACCINE;
D O I
10.1021/acs.jmedchem.7b00797
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Previous high throughput screening studies led to the discovery of two novel, nonlipid-like chemotypes as Toll-like receptor 4 (TLR4) agonists. One of these chemotypes, the pyrimido[5,4-b]indoles, was explored for structure activity relationship trends relative to production of TLR4 dependent cytokines/chemokines, resulting in a semioptimized lead (compound 1) that provided a starting point for further optimization studies. In this report, compounds belonging to three areas of structural modification were evaluated for biological activity using murine and human TLR4 reporter cells, primary murine bone marrow derived dendritic cells, and human peripheral blood mononuclear cells. The compounds bearing certain aryl groups at the C8 position, such as phenyl (36) and beta-naphthyl (39), had potencies significantly greater than compound 1. Compound 36 displayed human TLR4 agonist activity at submicromolar concentrations. The computational analysis suggests that the improved potency of these C8-aryl derivatives may be the result of additional binding interactions at the interface of the TLR4/myeloid differentiation protein-2 (MD-2) complex.
引用
收藏
页码:9142 / 9161
页数:20
相关论文
共 29 条
[21]   Design and Development of Stable, Water-Soluble, Human Toll-like Receptor 2 Specific Monoacyl Lipopeptides as Candidate Vaccine Adjuvants [J].
Salunke, Deepak B. ;
Connelly, Seth W. ;
Shukla, Nikunj M. ;
Hermanson, Alec R. ;
Fox, Lauren M. ;
David, Sunil A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (14) :5885-5900
[22]   Structure-Activity Relationship Analysis of Imidazoquinolines with Toll-like Receptors 7 and 8 Selectivity and Enhanced Cytokine Induction [J].
Schiaffo, Charles E. ;
Shi, Ce ;
Xiong, Zhengming ;
Olin, Michael ;
Ohlfest, John R. ;
Aldrich, Courtney C. ;
Ferguson, David M. .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (02) :339-347
[23]   Structure-Activity Relationships in Human Toll-Like Receptor 7-Active Imidazoquinoline Analogues [J].
Shukla, Nikunj M. ;
Malladi, Subbalakshmi S. ;
Mutz, Cole A. ;
Balakrishna, Rajalakshmi ;
David, Sunil A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (11) :4450-4465
[24]   The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells [J].
Smits, Evelien L. J. M. ;
Cools, Nathalie ;
Lion, Eva ;
Van Camp, Kirsten ;
Ponsaerts, Peter ;
Berneman, Zwi N. ;
Van Tendeloo, Viggo F. I. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (01) :35-46
[25]  
Steinman RM, 2006, CURR TOP MICROBIOL, V311, P17
[26]   TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS [J].
Wang, Ying ;
Su, Lijing ;
Morin, Matthew D. ;
Jones, Brian T. ;
Whitby, Landon R. ;
Surakattula, Murali M. R. P. ;
Huang, Hua ;
Shi, Hexin ;
Choi, Jin Huk ;
Wang, Kuan-Wen ;
Moresco, Eva Marie Y. ;
Berger, Michael ;
Zhan, Xiaoming ;
Zhang, Hong ;
Boger, Dale L. ;
Beutler, Bruce .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (07) :E884-E893
[27]   Potential adjuvantic properties of innate immune stimuli [J].
Warshakoon, Hemamali J. ;
Hood, Jennifer D. ;
Kimbrell, Matthew R. ;
Malladi, Subbalakshmi ;
Wu, Wen Yan ;
Shukla, Nikunj M. ;
Agnihotri, Geetanjali ;
Sil, Diptesh ;
David, Sunil A. .
HUMAN VACCINES, 2009, 5 (06) :381-394
[28]   Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study [J].
Wheeler, Cosette M. ;
Skinner, S. Rachel ;
Rowena Del Rosario-Raymundo, M. ;
Garland, Suzanne M. ;
Chatterjee, Archana ;
Lazcano-Ponce, Eduardo ;
Salmeron, Jorge ;
McNeil, Shelly ;
Stapleton, Jack T. ;
Bouchard, Celine ;
Martens, Mark G. ;
Money, Deborah M. ;
Quek, Swee Chong ;
Romanowski, Barbara ;
Vallejos, Carlos S. ;
ter Harmsel, Bram ;
Prilepskaya, Vera ;
Fong, Kah Leng ;
Kitchener, Henry ;
Minkina, Galina ;
Lim, Yong Kuei Timothy ;
Stoney, Tanya ;
Chakhtoura, Nahida ;
Cruickshank, Margaret E. ;
Savicheva, Alevtina ;
da Silva, Daniel Pereira ;
Ferguson, Murdo ;
Molijn, Anco C. ;
Quint, Wim G. V. ;
Hardt, Karin ;
Descamps, Dominique ;
Suryakiran, Pemmaraju V. ;
Karkada, Naveen ;
Geeraerts, Brecht ;
Dubin, Gary ;
Struyf, Frank .
LANCET INFECTIOUS DISEASES, 2016, 16 (10) :1154-1168
[29]   Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand [J].
Wu, Christina C. N. ;
Hayashi, Tomoko ;
Takabayashi, Kenji ;
Sabet, Mojgan ;
Smee, Donald F. ;
Guiney, Donald D. ;
Cottam, Howard B. ;
Carson, Dennis A. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (10) :3990-3995